ImmunoVaccize Technologies

IMV (formerly ImmunoVaccine Technologies) is a clinical-stage biopharmaceutical company that developed a novel class of immunotherapies based on its proprietary DPX delivery platform. The DPX technology is a unique lipid-based delivery system designed to program the immune system to produce a specific and durable immune response. The company's lead candidate, maveropepimut-S (MVP-S), is a T cell-activating immunotherapy targeting survivin-expressing cells, which has been evaluated in various oncology indications including ovarian cancer and diffuse large B-cell lymphoma. Despite promising clinical data, the company faced significant financial challenges and entered into creditor protection proceedings in 2023, leading to a cessation of most operations.